JP2016507521A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507521A5
JP2016507521A5 JP2015555498A JP2015555498A JP2016507521A5 JP 2016507521 A5 JP2016507521 A5 JP 2016507521A5 JP 2015555498 A JP2015555498 A JP 2015555498A JP 2015555498 A JP2015555498 A JP 2015555498A JP 2016507521 A5 JP2016507521 A5 JP 2016507521A5
Authority
JP
Japan
Prior art keywords
seq
binding protein
sequence shown
disease
motomeko
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015555498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507521A (ja
JP6539585B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2014/000066 external-priority patent/WO2014117220A1/en
Publication of JP2016507521A publication Critical patent/JP2016507521A/ja
Publication of JP2016507521A5 publication Critical patent/JP2016507521A5/ja
Application granted granted Critical
Publication of JP6539585B2 publication Critical patent/JP6539585B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015555498A 2013-02-01 2014-01-31 抗cd83抗体及びその使用 Expired - Fee Related JP6539585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759780P 2013-02-01 2013-02-01
US61/759,780 2013-02-01
PCT/AU2014/000066 WO2014117220A1 (en) 2013-02-01 2014-01-31 Anti-cd83 antibodies and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019000340A Division JP2019076102A (ja) 2013-02-01 2019-01-04 抗cd83抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2016507521A JP2016507521A (ja) 2016-03-10
JP2016507521A5 true JP2016507521A5 (enExample) 2017-02-23
JP6539585B2 JP6539585B2 (ja) 2019-07-03

Family

ID=51261317

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015555498A Expired - Fee Related JP6539585B2 (ja) 2013-02-01 2014-01-31 抗cd83抗体及びその使用
JP2019000340A Pending JP2019076102A (ja) 2013-02-01 2019-01-04 抗cd83抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019000340A Pending JP2019076102A (ja) 2013-02-01 2019-01-04 抗cd83抗体及びその使用

Country Status (13)

Country Link
US (3) US9840559B2 (enExample)
EP (2) EP2951208B1 (enExample)
JP (2) JP6539585B2 (enExample)
KR (2) KR102449868B1 (enExample)
CN (1) CN105531289B (enExample)
AU (1) AU2014213009B2 (enExample)
CA (1) CA2899960C (enExample)
DK (1) DK2951208T3 (enExample)
ES (1) ES2762622T3 (enExample)
MX (1) MX2015010023A (enExample)
NZ (1) NZ711543A (enExample)
PT (1) PT2951208T (enExample)
WO (1) WO2014117220A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2951208T (pt) 2013-02-01 2019-12-30 Univ California Anticorpos anti-cd83 e sua utilização
US10870704B2 (en) 2014-10-23 2020-12-22 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
US20200277396A1 (en) * 2017-09-13 2020-09-03 Kira Biotech Pty Limited Treatment Method
KR20200130324A (ko) * 2018-02-23 2020-11-18 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 Cd83-결합 키메라 항원 수용체
PH12022550141A1 (en) 2019-07-19 2023-12-04 Oncoresponse Inc Immunomodulatory antibodies and methods of use thereof
CA3147837A1 (en) * 2019-08-16 2021-02-25 Marco Davila Anti-cd83 chimeric antigen receptor expressing t regulatory cells
KR20220126654A (ko) * 2021-03-09 2022-09-16 (주)지아이이노베이션 IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형
CN117547553A (zh) * 2023-11-21 2024-02-13 中国人民解放军陆军特色医学中心 Cd83+、cd83+pd-l1+间充质干细胞及其制备方法和应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP2529321B2 (ja) 1986-04-28 1996-08-28 エンドトロニックス インコーポレーテッド 白血球を培養する方法
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
EP0569141A3 (en) 1992-04-14 1994-10-26 Hybritech Inc Method for inhibiting the growth of multidrug-resistant tumors by antibodies.
US5710262A (en) 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
US5316920A (en) 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6562622B1 (en) 1998-05-08 2003-05-13 Diatech Pty, Ltd Continuous in vitro evolution
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000042430A1 (en) 1999-01-15 2000-07-20 Medtox Scientific, Inc. Lateral flow test strip
HK1042648A1 (zh) * 1999-04-14 2002-08-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, C/O National Institutes Of Health, Office Of Technology Transfer 用於诱导对移植物的免疫耐受的含有免疫毒素和抑制树突细胞成熟的试剂的组合物
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン,エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2466845A1 (en) * 2001-11-21 2003-06-05 Fred Ramsdell Manipulation of cytokine levels using cd83 gene products
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2002950779A0 (en) 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004046729A2 (en) 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
EP2258724A1 (en) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulating immune responses using multimerized anti-CD83 antibodies
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP2008523083A (ja) * 2004-12-08 2008-07-03 イムノメディクス, インコーポレイテッド 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物
CA2602709A1 (en) 2005-03-31 2006-10-05 Telethon Institute For Child Health Research Isolation of inhibitor of ires-mediated translation
KR20150032915A (ko) * 2005-04-08 2015-03-30 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
JP2009504685A (ja) 2005-08-15 2009-02-05 アラーナ・テラピューティクス・リミテッド 新世界霊長類フレームワーク領域を用いる設計された抗体
CA2690973A1 (en) * 2006-06-23 2007-12-27 Paul M. Simon Targeted immune conjugates
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
US8197809B2 (en) 2008-06-25 2012-06-12 Korea Research Institute Of Bioscience And Biotechnology CD9-specific human antibodies
AR074369A1 (es) 2008-11-20 2011-01-12 Genentech Inc Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
WO2012088290A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
JP2013040160A (ja) * 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
PT2951208T (pt) 2013-02-01 2019-12-30 Univ California Anticorpos anti-cd83 e sua utilização
US10870704B2 (en) 2014-10-23 2020-12-22 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
US20200277396A1 (en) 2017-09-13 2020-09-03 Kira Biotech Pty Limited Treatment Method

Similar Documents

Publication Publication Date Title
TWI883026B (zh) 抗dll3嵌合抗原受體及其用途
JP2022071087A (ja) 抗cd38抗体および使用方法
JP2023071684A (ja) 抗bcma重鎖のみ抗体
JP2012501670A5 (enExample)
CN112955470A (zh) 抗tnfr2抗体及其用途
CN109563170B (zh) 抗gitr抗体及其用途
TW201031421A (en) IL-1 binding proteins
JP2012501669A5 (enExample)
WO2018137576A1 (zh) 抗pd-1单克隆抗体及其制备方法和应用
JP2012526558A5 (enExample)
KR20180083944A (ko) 항체 및 이의 사용 방법
TW201134487A (en) Therapeutic DLL4 binding proteins
JP7796034B2 (ja) ヒトcd45rcに特異的なキメラ抗原受容体およびその使用
US12071479B2 (en) Antibodies against ILT2 and use thereof
JP2017530119A (ja) リンパ球における阻害経路の中和
ES2737307T3 (es) Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer
KR20120104542A (ko) Il?1 결합 단백질
CN101512008A (zh) 白介素-13结合蛋白
AU2020328931A1 (en) Antibodies against ILT2 and use thereof
WO2012125680A1 (en) Methods of treating vasculitis using an il-17 binding molecule
CN113278071B (zh) 抗人干扰素α受体1单克隆抗体及其应用
CA3188068A1 (en) Multispecific binding agents and uses thereof
CN109071660A (zh) 预防移植物抗宿主疾病的方法
WO2022031680A1 (en) Cd47 binding agents and uses thereof
US20230303699A1 (en) Pd-l1 binding agents and uses thereof